Trial Outcomes & Findings for Clinical Importance of Treating Iron Overload in Sickle Cell Disease (NCT NCT00981370)
NCT ID: NCT00981370
Last Updated: 2017-02-08
Results Overview
Recruitment status
TERMINATED
Study phase
PHASE3
Target enrollment
1 participants
Primary outcome timeframe
Baseline, 6 months and 12 months
Results posted on
2017-02-08
Participant Flow
Subjects recruited from local physicians and at CHLA.
No groups for this study.
Participant milestones
| Measure |
Group One
No enrollment
|
|---|---|
|
Overall Study
STARTED
|
0
|
|
Overall Study
COMPLETED
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Clinical Importance of Treating Iron Overload in Sickle Cell Disease
Baseline characteristics by cohort
| Measure |
Group 1
First group of subjects to be enrolled.
|
|---|---|
|
Age, Customized
|
0
n=5 Participants
|
|
Gender
Female
|
0
n=5 Participants
|
|
Gender
Male
|
0
n=5 Participants
|
|
Liver Iron Concentration > 8mg/g dry weight
|
0
n=5 Participants
|
PRIMARY outcome
Timeframe: Baseline, 6 months and 12 monthsOutcome measures
Outcome data not reported
Adverse Events
Group 1
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place